与venetoclax相关的不良事件的风险评估:一个元分析方法
Tung-Lung Wu1, Chao-Kun Chen2, Chien-Ming Chao3
1Division of General Surgery, Department of Surgery, St. Martin De Porres Hospital, Chiayi City, Taiwan.
Expert opinion on drug safety
|January 20, 2025
概括
这一元分析表明,venetoclax增加了中性质减肥,腹和心血管事件的风险. 然而,它并没有显著增加瘤溶解综合征 (TLS) 的风险.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 维内托克拉克斯是一种口服B细胞淋巴瘤-2 (BCL-2) 抑制剂,具有癌症治疗潜力.
- 由于其新兴的用途,venetoclax的安全性需要彻底评估.
研究的目的:
- 进行一项元分析,评估venetoclax的安全性.
- 为了识别和量化与venetoclax治疗相关的不良事件.
主要方法:
- 在PubMed,Embase,Cochrane和ClinicalTrials.gov进行了系统的文献搜索,直到2023年8月.
- 使用随机效应模型分析了9项符合预定义纳入标准的研究.
- 为各种不良事件计算了风险比率 (RR) 和95%置信区间 (CI).
主要成果:
- 威尼托克拉克斯的使用与中性质衰竭的风险显著增加有关 (RR=1.427,95% CI=1.118-1.822).
- 还观察到腹 (RR=1.889,95% CI=1.388-2.570) 和心血管事件 (RR=1.726,95% CI=1.088-2.737) 的风险增加.
- 使用venetoclax时,瘤溶解综合征 (TLS) 的风险没有显著增加 (RR=1.478,95% CI=0.504-4.337).
结论:
- 威尼托克拉克斯与血液学,胃肠道和心脏不良事件的风险更高有关.
- 对这些副作用的临床监测至关重要,特别是在患有先前疾病的患者中.
- 需要进一步的研究,以全面了解venetoclax.com的安全性.
更多相关视频
07:40A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
4.1K
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
8.2K
相关概念视频
01:19Pharmacovigilance
770
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
770
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
115
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
115
01:12Hazard Ratio
83
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
83
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
230
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
230
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147